Literature DB >> 234828

Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite.

K L Hintze, J S Wold, L J Fischer.   

Abstract

Radioactivity was excreted in the urine and feces of rats, mice, and humans after a dose of 14C-cyproheptadine. The major metabolite in rat urine was unconjugated, but the majority of radioactive materials in mouse and human urine were conjugated with glucuronic acid. Identification of the rat urinary metabolite of cyproheptadine as an epoxide was accomplished with mass spectrometry and other methods. The rat metabolite was 10.11 -epoxydesmethylcyproheptadine and accounted for about 25% of a 45-mg dose of cyproheptadine per kg. Only a small amount of this epoxide was found in mouse urine, and none was apparent in the urine of two humans who received 5 mg of the drug. Dihydrodiols, which could arise by epoxide hydrase hydrolysis of possible 10.11-epoxy metabolites, were not found in the urine of any of the species studied. The spoxide found in rat urine appears to be unusually stable to in vivo hydrolysis. Possible implications of these results in the species-selective pancreotoxicity of cyproheptadine in the rat are presented.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 234828

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.

Authors:  J Vincent; R Liminana; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

2.  Inhibition of liver microsomal epoxide hydrase by cyproheptadine epoxide.

Authors:  J Pachecka; M Salmona; G Belvedere; L Cantoni; E Mussini; S Garattini
Journal:  Experientia       Date:  1977-04-15

3.  Cyproheptadine metabolites inhibit proinsulin and insulin biosynthesis and insulin release in isolated rat pancreatic islets.

Authors:  S A Chow; J L Falany; L J Fischer
Journal:  Cell Biol Toxicol       Date:  1989-06       Impact factor: 6.691

Review 4.  Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).

Authors:  D M Paton; D R Webster
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

5.  Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.

Authors:  Yu-Min Feng; Chin-Wen Feng; Syue-Yi Chen; Hsiao-Yen Hsieh; Yu-Hsin Chen; Cheng-Da Hsu
Journal:  BMC Cancer       Date:  2015-03-17       Impact factor: 4.430

6.  Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort.

Authors:  Ronald Kong; Jiyuan Ma; Brian Beers; Diksha Kaushik; E Lin; Elizabeth Goodwin; Joseph Colacino; Francesco Bibbiani
Journal:  Pharmacol Res Perspect       Date:  2020-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.